Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Eyes of Pelobresso

The stock today is 27. At the current price, more than half of that value would be covered by the net cash at the end of this year. So you're paying for less than $13 per share net, you're getting Pelobresso which I think you guys think risk adjusted could be worth as much as $45 per share. We are active engagement in lifetimes. That's the exposure we give to our investors. And when we sat down with John Paul, who's the CEO here, we went through section A, section B, and we came to section C,. The reason why we thought they'd underperformed was obviously, we thought that Majouvi was potentially

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner